Lahouel K, Douville C, Diergaarde B, Cohen JD, Grant H, Kuo A, Ansari SK, Wang Y, O’Broin-Lennon AM, Popoli M, Ptak J, Silliman N, Dobbyn L, Nehme N, Tie J, Gibbs P, Papadopoulos N, Kinzler KW, Vogelstein B, Schoen RE, Tomasetti C. A Blood-based Assay for Detection of Patients with Advanced Adenomas.Cancer Research Communications. 2025;:10.1158/2767-9764.crc-24-0398
Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. 2025;:10.1038/s41591-025-03579-w
Kim GY, Jalali A, Gard G, Yeung JM, Chau H, Gately L, Houli N, Jones IT, Kosmider S, Lee B, Lee M, Nott L, Shapiro JD, Tie J, Thomson B, To YH, Wong V, Wong R, Dunn C, Johns J, Gibbs P. Initial Assessment of Resectability of Colorectal Cancer Liver Metastases Versus Clinical Outcome. Clinical Colorectal Cancer. 2025;24(1):10.1016/j.clcc.2024.10.001
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, Kukard C, Jayawardana M, Silva SSM, Alexander M, Tie J, Galettis P, Martin JH. Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial. British Journal of Clinical Pharmacology. 2025;:10.1002/bcp.70006
Dunn C, Tie J, Gibbs P. A Call for Improved Guidance to Integrate Modern Biomarkers Into Routine Clinical Care—Piecing the Puzzle Together. JAMA Oncology. 2025;11(4):10.1001/jamaoncol.2024.6479
Piercey O, Chantrill L, Hsu H, Ma B, Price T, Tan IB, Teng H, Tie J, Desai J. Expert consensus on the optimal management of BRAFV600E‐mutant metastatic colorectal cancer in the Asia‐Pacific region. Asia-Pacific Journal of Clinical Oncology. 2025;21(1):10.1111/ajco.14132
Hitchen N, Wong H-L, Wong R, Shapiro JD, Burge ME, Nott LM, Lee B, Lim SH-S, Wong SF, Caird S, Wong V, Rainey NH, Khattak A, Mandaliya HA, Hayes TM, Torres J, Jalali A, Campbell A, Gibbs P, Tie J. Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.Journal of Clinical Oncology. 2025;43(4_suppl):10.1200/jco.2025.43.4_suppl.70
Hitchen N, Shahnam A, Tie J. Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors with Prognostic and Predictive Value. Annual Review of Medicine. 2025;76(1):10.1146/annurev-med-100223-090016
Loft M, Wong V, Kosmider S, Wong R, Shapiro J, Hong W, Jennens R, Tie J, Caird S, Steel S, Lee B, Nott L, Khattak MA, Lim S, Chong G, Hayes T, Underhill C, McLachlan S, Rainey N, Dunn C, Gibbs P. Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer. Internal Medicine Journal. 2025;55(1):10.1111/imj.16575
Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab plus 5-Fluorouracil as first-line therapy for older patients with RAS and BRAF wild type metastatic colorectal cancer. A study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2024;:10.1016/j.clcc.2024.11.003
